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Abstract
Background: Gene therapy has tremendous potential for both inherited and acquired diseases. However, delivery problems
limited their clinical application, and new gene delivery vehicles with low cytotoxicity and high transfection efficiency are
greatly required.
Methods: In this report, we designed and synthesized three amphiphilic molecules (L1–L3) with the structures involving 1,
4, 7, 10-tetraazacyclododecane (cyclen), imidazolium and a hydrophobic dodecyl chain. Their interactions with plasmid DNA
were studied via electrophoretic gel retardation assays, fluorescent quenching experiments, dynamic light scattering and
transmission electron microscopy. The in vitro gene transfection assay and cytotoxicity assay were conducted in four cell
lines.
Results: Results indicated that L1 and L3-formed liposomes could effectively bind to DNA to form well-shaped
nanoparticles. Combining with neutral lipid DOPE, L3 was found with high efficiency in gene transfer in three tumor cell
lines including A549, HepG2 and H460. The optimized gene transfection efficacy of L3 was nearly 5.5 times more efficient
than that of the popular commercially available gene delivery agent Lipofectamine 2000
TM in human lung carcinoma cells
A549. In addition, since L1 and L3 had nearly no gene transfection performance in normal cells HEK293, these cationic lipids
showed tumor cell-targeting property to a certain extent. No significant cytotoxicity was found for the lipoplexes formed by
L1–L3, and their cytotoxicities were similar to or slightly lower than the lipoplexes prepared from Lipofectamine 2000
TM.
Conclusion: Novel cyclen-based cationic lipids for effective in vitro gene transfection were founded, and these studies here
may extend the application areas of macrocyclic polyamines, especially for cyclen.
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Introduction
Gene therapy, as a promising therapeutics to treat genetic or
acquired diseases, has received significant attentions in the past
several decades due to its advantages over traditional therapies [1–
3]. The clinical success of gene therapy continues to remain
critically dependent on the availability of safe and efficacious gene
delivery reagents, popularly known as transfection vectors [4,5].
Comparing to viral gene vectors, for the lesser immunogenic
nature, robust manufacture ability to deliver large pieces of DNA,
and ease of handling and preparation techniques, cationic lipids as
non-viral vectors have attracted an upsurge of global interest in
recent years for gene delivery [2,6].
Since Felgner et al. first reported the utilization of unnatural
diether-linked cationic lipid, N-[1-(2, 3-dioleyloxy) propyl]-N, N,
N-trimethylammonium chloride (DOTMA), as a synthetic carrier
to deliver gene into cells in 1987 [7], design and syntheses of more
efficient cationic lipids [2,6,8] have been reported. The visible
fruits of such intense global efforts toward developing safe and
efficient cationic lipids for use in gene delivery are a number of
commercially available cationic lipid-based transfection kits such
as Lipofectamine and Lipofectamine 2000
TM [9]. However, those
cationic lipids were still far from the requirement of gene therapy
because of their relative low transfection efficiency and potential
cytotoxicity [10,11]. Consequently, the development of novel
nontoxic cationic structures high gene transfection efficiencies is of
great importance.
Many cationic amphiphiles involving linear polyamines [12,13]
or branched polyamines [14] have been widely studied. Although
cationic lipids using polyamine as the headgroups always show
higher gene transfection efficiency than those containing one
quaternary amine or single protonated amine [15–17], cationic
lipids with long linear polyamine chains as headgroups might also
have decreased gene delivery efficiency because of their relatively
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folding of the linear lipopolyamine chains in the structure [18].
Since cyclic polyamines and branched polyamines are hard to self-
fold, we postulated that using macrocyclic polyamines as the
hydrophilic headgroups of cationic lipids may solve this problem.
To the best of our knowledge, there is no example using cyclic
polyamines as the hydrophilic headgroup of cationic lipid for gene
delivery. Our previous studies revealed that some 1, 4, 7, 10-
tetraazacyclododecane (cyclen) based cationic lipids [19] or linear
[20] and reticular [21] polymers, which could transfer plasmid
DNA into cells without use of extraneous agent. However, the
transfection efficiency (TE) was not satisfying. It is necessary to
further investigate the structure-activity relationship (SAR) of this
type of cationic lipids. In addition, cationic lipids containing
imidazolium polar heads [22,23] have been reported to display
higher transfection efficiency and reduced cytotoxicity when
compared with classical quaternary ammonium cationic lipids.
In the present study, we designed and synthesized three cationic
lipids L1–L3 (Figure 1), which have the same hydrophilic
headgroup (protonated cyclen and imidazolium salt). Their
hydrophobic alkyl chains were connected to the headgroup via
methylene (L1) or ester groups (L2 and L3), and the sole structural
difference between L2 and L3 is the orientation of the ester group.
Their interactions with plasmid DNA and the properties of formed
lipoplexes were examined. The in vitro transfection efficiencies
towards four cell lines were investigated to study the SAR of this
type of cationic lipids in gene delivery. Results indicated that tiny
difference in the lipid structures might lead to essential distinction
in the in vitro transfection efficiency, and L3 has much higher
luciferase reporter gene transfection efficiency than Lipofectamine
2000
TM in human lung carcinoma cell line A549.
Materials and Methods
Materials
Unless stated otherwise, all chemicals and reagents were
obtained commercially and used without further purification.
Absolute chloroform (CHCl3) and dichloromethane (CH2Cl2)
were distilled from calcium hydride (CaH2) and anhydrous
acetonitrile (CH3CN) from phosphorus pentoxide. The precursor
1-bromomethyl-4-(4, 7, 10 tris(tertbutyloxycarbonyl)-19,4 9,7 9,
109-tetraazacyclododecan-1-yl-methylene)benzene (3) were pre-
pared according to the literature [24]. IR spectra were recorded
on a Shimadzu FTIR-4200 spectrometer as KBr pellets or thin
films on KBr plates. The
1H NMR and
13C NMR spectra were
measured on a Varian INOVA-400 spectrometer and the d scale
in parts per million was referenced to residual solvent peaks or
internal tetramethylsilane (TMS). MS-ESI spectra data were
recorded on a Finnigan LCQDECA and a Bruker Daltonics
BioTOF mass spectrometer respectively. Fluorescence spectra
were measured by a Horiba Jobin Yvon Fluoromax-4 spectroflu-
orometer. MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetra-
zolium bromide) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). MicroBCA protein assay kit was obtained from Pierce
(Rockford, IL, USA). Luciferase assay kit was purchased from
Promega (Madison, WI, USA). Endotoxin free plasmid purifica-
tion kit was purchased from TIANGEN (Beijing, China). The
plasmids used in the study were pGL-3 (Promega, Madison, WI,
USA) coding for luciferase DNA and pEGFP-N1 (Clontech, Palo
Alto, CA, USA) coding for EGFP DNA. The Dulbecco’s Modified
Eagle’s Medium (DMEM), RPMI 1640 Medium and fetal bovine
serum were purchased from Invitrogen Corp. A549 (Human lung
adenocarcinoma epithelial cells), HEK 293 (human embryonic
kidney cells), Hep G2 (Human hepatocellular carcinoma cells),
and H460 (Human lung cancer cells) cell lines were purchased
from the American Type Culture Collection (ATCC).
Synthesis of dodecyl chloroacetate (1b)
Chloroacetyl chloride (16.5 g, 150 mmol) in anhydrous dichlo-
romethane (25 mL) was added dropwise to a stirred solution of 1-
dodecanol (5 g, 30 mmol) and triethylamine (4.8 mL, 3.5 g,
34.5 mmol) in anhydrous dichloromethane (100 mL). The result-
ing reaction mixture was stirred for 4 h at room temperature (r. t.).
Excess chloroacetyl chloride was removed by washing with a 5%
solution of sodium hydrogen carbonate (50 mL63) and brine
(50 mL61). The organic phase was dried over anhydrous
magnesium sulfate, filtered, and rotary-evaporated. The resulting
dodecyl chloroacetate (1b) was obtained as yellow oil, weighed
7.21 g, corresponding to 91% yield. IR (cm
21): 2926, 2855, 1760,
1463, 1415, 1381, 1307, 1177, 996, 790.
1H NMR (CDCl3,
400 MHz): d 0.89 (t, J=9.2 Hz, 3H, CH2CH3), 1.27–1.37 (m,
16H, (CH2)8CH3), 1.67 (m, 2H, COCH2CH2), 4.07 (s, 2H,
ClCH2CO), 4.19 (t, J=8.8 Hz, 2H, COCH2CH2).
13C NMR
(CDCl3, 100 MHz): 14.10, 22.68, 25.75, 28.43, 29.17, 29.33,
29.46, 29.54, 29.61, 31.90, 40.93, 66.42, 167.39. ESI MS:
285(M+Na
+).
Synthesis of 2-chloroethyl laurate (1c)
The 2-chloroethyl laurate (1c) was synthesized according to the
similar procedures described in reported literature [25]. Briefly, to
pure thionyl chloride (25 mL, 42 g, 352 mmol) was added lauric
acid (10 g, 50 mmol) gradually. The resulting mixture was heated at
reflux for about 1 h. The excess thionyl chloride was removed under
reduced pressure. Lauroyl chloride was obtained as a brown oil
liquid (9.2 g, 40 mmol) which was directly used in the next step
without further purification. The obtained lauroyl chloride (9.2 g,
40 mmol) in anhydrous dichloromethane (15 mL) was added
dropwise to a stirred solution of 2-chloroethyl alcohol (2.7 g,
30 mmol) and triethylamine(4.8 mL, 3.5 g, 35 mmol) in anhydrous
dichloromethane (50 mL). The resulting reaction mixture was
stirred for 4 h at room temperature and then washed with 5%
solution of sodium hydrogen carbonate (30 mL63) and brine
(30 mL61). The organic phase was dried over anhydrous
magnesium sulfate, filtered, and rotary-evaporated to get crude
2-chloroethyl laurate as brown oil. Pure 2-chloroethyl laurate was
obtained as a yellow liquid by flash chromatography over silica
(petroleum ether/ethyl acetate, 20/1), weighed 6.4 g, corresponding
Figure 1. Molecular structures of target lipids (L1, L2 and L3).
doi:10.1371/journal.pone.0023134.g001
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21): 3467, 2926, 2679, 1742, 1461, 1384.
1H
NMR (CDCl3, 400 MHz): d 0.88 (t, J=13.6 Hz, 3H, CH2CH3),
1.22–1.30 (br,16H,(CH2)8CH3),1.64 (m,2H,COCH2CH2),2.35(t,
J=15.2 Hz, 2H, COCH2), 3.68 (t, J=11.6 Hz, 2H, CH2OCO),
4.33 (t, J=11.6 Hz, 2H, ClCH2).
13C NMR (CDCl3, 100 MHz):
14.08, 22.66, 24.87, 29.07, 29.22, 29.31, 29.43, 29.57, 31.89, 34.06,
41.61, 63.77, 173.45. ESI MS: 263 (M+H
+), 285 (M+Na
+).
General Synthesis of imidazole derivatives (2a, 2b and 2c)
Halogen derivatives(1a, 1b or 1c) (22.6 mmol) was added to a
solution of imidazole (18.46 g, 271 mmol), sodium carbonate
(2.4 g, 23 mmol), potassium iodine (0.2 g, 1.2 mmol) in anhydrous
chloroform (30 mL) and dimethyl sufloxide (20 mL). The reaction
mixture was heated at 90uC for 10 h, then chloroform (150 mL)
was added. The resulting reaction mixture was washed with 5%
solution of sodium hydrogen carbonate (100 mL63) and brine
(100 mL61). The organic phase was dried over anhydrous
magnesium sulfate, filtered, and rotary-evaporated to get crude
residue which were purified by flash, chromatography over silica
(ethyl acetate) to obtain the corresponding imidazole derivatives
2a, 2b and 2c.
N-Dodecylimidazole (2a): yellow oil liquid, yield 88%. IR
(cm
21): 3388, 3107, 2925, 2854, 1506, 1465, 1376.
1H NMR
(CDCl3, 400 MHz): d 0.88 (t, J=13.6 Hz, 3H, CH2CH3), 1.25–
1.30 (m, 18H, (CH2)9CH3), 1.77 (m, 2H, COOCH2CH2), 3.92 (t,
J=14 Hz, 2H, COOCH2CH2), 6.90 (d, 1H, imidazole-H), 7.05
(d, 1H, imidazole-H), 7.48 (s, 1H, imidazole-H).
13C NMR
(CDCl3, 100 MHz): 14.13, 22.69, 26.55, 29.07, 29.33, 29.43,
29.52, 29.60, 31.09, 31.90, 47.04, 118.76, 129.34, 137.06. ESI
MS: 237 (M+H
+), 259 (M+Na
+).
1H-Imidazole-1-acetic acid, dodecyl ester (2b): white solid, yield
90%. IR (cm
21): 3472, 3117, 2958, 2921, 2851, 1744, 1512, 1210.
1H NMR (CDCl3, 400 MHz): d 0.88 (t, J=13.6 Hz, 3H,
CH2CH3), 1.26–1.30 (br, 18H, (CH2)9CH3), 1.64 (m, 2H,
COOCH2CH2), 4.17 (t, J=13.6 Hz, 2H, COOCH2CH2), 4.70
(s, 2H, NCH2COO), 6.96 (d, 1H, imidazole-H), 7.10 (d, 1H,
imidazole-H), 7.51 (s, 1H, imidazole-H).
13C NMR (CDCl3,
100 MHz): 14.10, 18.43, 22.67, 25.72, 28.39, 29.13, 29.32, 29.44,
29.52, 29.60, 31.89, 48.06, 58.13, 66.23, 119.94, 129.65, 137.91,
167.47. ESI MS: 295.4 (M+H
+).
Dodecanoic acid, 2-(1H-imidazol-1-yl)ethyl ester (2c): yellow oil
liquid, yield 86%. IR (cm
21): 3381, 3112, 2925, 2854, 1740, 1507,
1461.
1H NMR (CDCl3, 400 MHz): d 0.88 (t, J=13.6 Hz, 3H,
CH2CH3), 1.22–1.40 (br, 16H, (CH2)8CH3), 1.60 (m, 2H,
COOCH2CH2), 2.31 (t, J=15.2 Hz, 2H, COOCH2CH2), 4.20
(t, J=10.4 Hz, 2H, NCH2CH2O), 4.33 (t, J=10.4 Hz, 2H,
CH2OCO), 6.99 (d, 1H, imidazole-H), 7.10 (d, 1H, imidazole-H),
7.54 (s, 1H, imidazole-H).
13C NMR (CDCl3, 100 MHz): 14.09,
22.65, 24.76, 29.04, 29.18, 29.30, 29.40, 29.55, 31.87, 34.01,
45.84, 62.97, 173.31. ESI MS: 295.2 (M+H
+).
General synthesis of precursors (4a, 4b and 4c)
A solution of imidazole derivatives (2a, 2b or 2c) (5 mmol) and
1-bromomethyl-4-(4, 7, 10-tris-(tert-butyloxycarbonyl)-1, 4, 7, 10-
tetraazacyclododecan-1-yl-methyl)benzene (3, 0.66 g, 10 mmol) in
anhydrous acetonitrile (20 mL) was refluxed at 90uC over a period
of 48–96 h, after which TLC indicated the disappearance of the
starting material imidazole derivatives. Then reaction mixture was
cooled and the acetonitrile was rotary-evaporated to yield a yellow
residue, which was purified by chromatography over silica
(dichloromethane/methanol, 20:1) to obtain white foamy solid in
50–68% yield.
Compound 4a: IR (cm
21): 2926, 2854, 1692, 1461, 1415, 1366,
1249, 1160.
1H NMR (CDCl3, 400 MHz): d 0.87 (t, J=6.8 Hz,
3H, CH2CH3), 1.25–1.47 (br, 45H, (N-Boc)3 and (CH2)9CH3), 1.92
(m, 2H, NCH2CH2), 2.64 (m, 4H, cyclen-H), 3.30–3.57 (br, 12H,
cyclen-H), 3.72 (s, 2H, ArCH2-cyclen), 4.30 (t, J=15.2 Hz, 2H,
imidazole-CH2CH2), 5.59 (s, 2H, ArCH2-imidazole), 7.12 (d, 1H,
imidazole-H), 7.17 (d, 1H, imidazole-H), 7.30–7.32 (d, 2H, Ar-H),
7.40–7.42 (d, 2H, Ar-H). HRMS (C46H79N6O6): Calcd. 811.6061;
Found. 811.6046.
Compound 4b: IR (cm
21): 3365, 2926, 2855, 1750, 1691, 1563,
1461, 1415, 1365, 1249, 1165.
1H NMR (CDCl3, 400 MHz): d
0.88 (t, J=9.2 Hz, 3H, CH2CH3), 1.26–1.56 (br, 45H, (CH2)9CH3
and (N-Boc)3), 1.66 (m, 2H, COCH2CH2), 2.48–2.64 (m, 4H,
PhN(CH2)2), 3.31–3.80 (m, 14H, cyclen-H and Ar-CH2-cyclen),
4.19 (t, J=7.2, 2H, COOCH2), 5.44 (s, 2H, Ar-CH2-imidazole),
5.52 (s, 2H, imidazole-CH2-COO), 7.31–7.47 (m, 4H, Ar-H), 7.54
(s, 1H, imidazole-H), 7.56 (s, 1H, imidazole-H), 10.39 (s, 1H,
imidazole-H).
13C NMR (CDCl3, 100 MHz): 14.10, 22.65, 25.69,
25.75, 28.33, 28.45, 28.65, 29.16, 29.23, 29.43, 29.45, 29.56,
29.58, 29.60, 31.88, 32.79, 50.28, 53.33, 62.93, 67.10, 79.60,
123.74, 128.90, 166.07. ESI MS: 869 (M
+), 812 (M
+-CH2CH2
CH2CH3).
Compound 4c: IR (cm
21): 3431, 2973, 2928, 2855, 1741, 1690,
1563, 1461, 1415, 1366, 1250, 1159.
1H NMR (CDCl3,
400 MHz): d 0.87 (t, J=13.6 Hz, 3H, CH2CH3), 1.11–1.33 (br,
16H, (CH2)8CH3), 1.43–1.57 (br, 27H, (N-Boc)3), 1.64 (m, 2H,
COOCH2CH2), 2.33 (t, J=15.2 Hz, 2H, COOCH2CH2), 2.64
(m, 4H, cyclen-H), 3.30–3.69 (br, 12H, cyclen-H), 3.76 (s, 2H,
ArCH2-cyclen), 4.51 (t, J=9.6 Hz, 2H, CH2OCO), 4.76 (t,
J=8.8 Hz, 2H, NCH2CH2OCO), 7.31 (d, 2H, Ar-H), 7.41 (d,
1H, imidazole-H), 7.48 (d, 2H, Ar-H), 7.70 (d, 1H, imidazole-H),
10.44 (d, 1H, imidazole-H).
13C NMR (CDCl3, 100 MHz): 22.04,
22.49, 24.58, 28.35, 28.54, 28.94, 29.15, 29,32, 29.45, 30.75,
31.72, 33.80, 47.56, 49.01, 49.73, 50.26, 52.76, 52.96, 54.24,
54.95, 55.95, 60.01, 60.96, 61. 98, 79.29, 79.36, 121.87, 123.04,
128.83, 130.95, 131.80, 137.14, 138.26, 155.29, 155.63, 172.87,
206.63. ESI MS: 869.9 (M
+).
General Synthesis of L1, L2 and L3
Precursor (4a, 4b or 4c, 1 mmol) was suspended in anhydrous
dichloromethane (10 mL), and then a solution of trifluoroacetic
acid (5 mL) in anhydrous dichloromethane (5 mL) was added
dropwise under ice-cold water and N2 atmosphere. The obtained
mixture was stirred at room temperature for 6 h. The solvent and
excess trifluoroacetic acid were removed under reduced pressure
to obtain the final lipids as a yellow liquid in 98–100% yield.
Lipid L1: IR (KBr, cm
21): 3417, 2925, 1794, 1687, 1562, 1515,
1460, 1354, 1269, 1199, 1044, 934, 823, 747.
1H NMR (CDCl3,
400 MHz): d 0.87 (t, J=9.9 Hz, 3H, CH2CH3), 1.26 (br s, 18H,
(CH2)9CH3), 1.83 (m, 2H, NCH2CH2), 2.89–2.91 (m, 4H,
PhN(CH2)2), 3.04 (m, 4H, PhN(CH2CH2)2), 3.19–3.25 (m, 8H,
N(CH2CH2)2), 3.86 (s, 2H, ArCH2N(CH2CH2)2), 4.20 (t,
J=10.8 Hz, 2H, (CH)(CH)NCH2CH2), 5.41 (s, 2H,
ArCH2N(CH)(CH)), 7.43 (m, 4H, CH2ArCH2), 7.52 (d, 1H,
imidazole-H), 7.54 (d, 1H, imidazole-H), 9.01 (s, 1H, imidazole-
H).
13C NMR (DMSO-d6): 14.40, 22.55, 26.04, 28.81, 29.16,
29.28, 29.38, 29.46, 29.98, 31.14, 31.75, 42.59, 42.71, 45.22,
47.74, 48.80, 49.47, 121.10, 122.23, 123.05, 123.31, 127.91,
128.01, 128.85, 129.77, 130.10, 131.03, 134.37, 134.45, 134.48,
134.54, 135.85, 136.66, 206.89. HRMS (C31H55N6
+): Calcd.
511.4488; Found 511.4442.
Lipid L2: IR (KBr, cm
21): 3411, 2926, 2855, 1749, 1684, 1565,
1460, 1201, 1170, 1128, 828, 799, 719.
1H NMR (DMSO-d6,
400 MHz): d 0.86 (t, J=12.8 Hz, 3H, CH2CH3), 1.16–1.25 (br s,
18H, (CH2)9), 1.60 (m, 2H, COOCH2CH2), 2.73 (m, 4H,
PhN(CH2)2), 2.85–2.92 (m, 4H, PhN(CH2CH2)2), 3.06–3.14
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2H, COOCH2CH2), 5.30 (s, 2H, ArCH2N(CH)(CH)), 5.53 (s, 2H,
(CH)(CH)NCH2CO), 7.34–7.51 (m, 4H, CH2ArCH2), 7.80 (s, 1H,
imidazole-H), 7.88 (s, 1H, imidazole-H), 9.37 (s, 1H, imidazole-H).
13C NMR (DMSO-d6): 22.51, 25.66, 28.40, 29.05, 29.13, 29.35,
29.41, 29.43, 29.47, 31.72, 39.42, 39.62, 39.83, 40.04, 42.57,
42.75, 45.22, 47.77, 50.14, 52.24, 55.66, 66.23, 122.73, 124.71,
128.84, 131.03, 134.21, 136.62, 137.95, 167.30. HRMS
(C33H57N6O2
+): Calcd. 569.4543; Found 569.4468.
Lipid L3: IR (KBr, cm
21): 2926, 2855, 1714, 1673, 1460, 1410,
1199, 1137, 832, 800, 721.
1H NMR (DMSO-d6, 400 MHz): d
0.78 (t, J=13.2 Hz, 3H, CH2CH3), 1.09–1.22 (br, 16H,
(CH2)8CH3), 1.38 (m, 2H, COOCH2CH2), 2.21 (t, J=14.8 Hz,
2H, OCOCH2CH2), 2.65 (m, 4H, PhN(CH2)2), 2.78–2. 82 (m, 4H,
N(CH2CH2)2), 2.99–3.18 (m, 8H, N(CH2CH2)2), 3.85 (s, 2H,
ArCH2N(CH2CH2)2), 4.33 (t, J=9.6 Hz, 2H, CH2OCO), 4.43 (t,
J=8.8 Hz, 2H, NCH2CH2O), 5.40 (s, 2H, ArCH2N(CH)(CH)),
7.30–7.36 (m, 4H, CH2ArCH2), 7.77 (s, 1H, imidazole-H), 9.36 (s,
1H, imidazole-H).
13C NMR (DMSO-d6): 22.54, 24.66, 28.82,
29.10, 29.15, 29.31, 29.44, 31.74, 33.62, 39.36, 39.57, 39.78,
39.99, 42.52, 42.63, 45.14, 47.58, 48.71, 52.10, 55.43, 59.81,
62.22, 123.01, 123.72, 128.76, 131.01, 134.35, 136.35, 137.23,
172.98. HRMS (C33H57N6O2
+): Calcd. 569.4543; Found
569.4540.
Amplification and purification of plasmid DNA
pGL-3 and pEGFP-N1 plasmids were used. The former one
was used as the luciferase reporter gene which was transformed in
JM109 Escherichia coli, and the latter one was used as the
enhanced green fluorescent protein reporter gene which was
transformed in E. coli DH5a. Both plasmids were amplified in E.
coli grown in LB media at 37uC and 220 rpm overnight. The
plasmids were purified by an EndoFree TiangenTM Plasmid Kit.
Then the purified plasmids were dissolved in TE buffer solution
and stored at 220uC. The integrity of plasmids was confirmed by
agarose gel electrophoresis. The purity and concentration of
plasmids were determined by the ratio of ultraviolet (UV)
absorbances at 260 nm to 280 nm.
Preparation of cationic liposome
All cationic lipids were stored as stock solutions in anhydrous
chloroform at 220uC under argon. Individual cationic lipid
(0.005 mmol) or its mixture with DOPE in the desired mole ratio
was dissolved in anhydrous chloroform (5 mL) in autoclaved glass
vials. Thin films were made by slowly rotary-evaporating the
solvent at room temperature. Last traces of organic solvent were
removed by keeping these films under vacuum above 8 h. The
dried films and freshly autoclaved tris buffer (10 mM, PH 7.4) was
preheated to 70uC, then the tris buffer (5 mL) was added to the
films such that the final concentration of the cationic lipid was
1 mM. The mixtures were vortexed vigorously until the films were
completely resuspended. Sonication of these suspensions for
20 min in a bath sonicator at 60uC afforded the corresponding
cationic liposomes which were stored at 4uC.
Preparation of liposome/pDNA complexes (lipoplexes)
To prepare the cationic lipid/pDNA complexes (lipoplexes),
various amounts of cationic lipid in liposome solutions were mixed
with a constant amount of DNA by pipetting thoroughly at various
N/P ratios, and incubated for 30 min at room temperature. The
theoretical N/P ratio of lipid to DNA represents the ratio of
charge on cationic lipid (in mol) to nucleotide base molarity and
was calculated by considering the average nucleotide mass of 350.
Gel retardation assay
To determine the formation of liposome/DNA complex
(lipoplexes), lipoplexes of various N/P ratios ranging from 0 to 8
were prepared as described above. Constant amount of 5 mg DNA
was used here. 10 mL of each lipoplexes solution were electropho-
resed on the 1% (W V-1) agarose gel containing Gold view and
Tris-acetate (TAE) running buffer at 110 V for 30 min. DNA was
visualized with a UV lamp using a BioRad Universal Hood II.
Ethidium bromide intercalation assay
Fluorescence emission due to ethidium bromide (EB) at 605 nm
was monitored in a Fluoromax-4 spectrofluorimeter (Excitation
wavelength was 497 nm with 3 nm slit widths for both excitation
and emission). Typically fluorescence emission was measured for
EB (5 mM) in 10 mM Tris, pH 7.4 buffer. To this solution CT-
DNA (11 mM) was added and the fluorescence emission due to EB
upon intercalative complexation with DNA was measured again at
25uC. Then aliquots of a given cationic liposome (0.68 mM) were
added into the EB/CT-DNA solution for further measurement. If
F0 is the fluorescence intensity (FI) of unintercalated and Fmax is
the FI of fully intercalated EB, and Fx is the FI for a given
concentration of liposome, then %FI was calculated as
%FI=(Fx2F0)/(Fmax2F0)6100.
Dynamic light scattering (DLS)
Particle size and zeta-potential of liposomes or lipoplexes at
various N/P ratio were measured by a dynamic light scattering
system (Zetasizer Nano ZS, Malvern Instruments Led) at 25uC.
Transmission electron microscopy
The morphology and particle size distribution of the liposomes
and lipoplexes were examined using a TecnaiG
2 F20 Transmission
Electron Microscope (TEM) operated at 200 keV. A drop of
lipoplex suspensions at optimized lipid/DOPE/DNA ratios (as in
the final luciferase expression assay) was added to carbon coated
400-mesh copper grids, and allowed to adsorb for about 30 s
followed by negative staining with a drop of 0.5% v/v
phosphotungstic acid. Excess stain was removed after 1 min and
the grids were air dried at room temperature before observing
under TEM.
Cell culture
A549 (Human lung adenocarcinoma epithelial cells), Hep G2
(Human hepatocellular carcinoma cells), and H460 (Human lung
cancer cells) cell lines were incubated in RPMI medium 1640
containing 10% fetal bovine serum (FBS) and 1% antibiotics(pe-
nicillin-streptomycin, 10000 U mL-1), HEK 293 (human embry-
onic kidney cells) were incubated in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% fetal bovine serum (FBS) and
1% antibiotics. All cells were maintained at 37uC under an
atmosphere of 5% CO2–95% air.
Transfection procedure
24-well plates were seeded with 45000–60000 cell/well in
500 mL antibiotic-free media 24 h before transfection in order to
obtain about 80%–90% confluent cultures at the time of
transfection. For the preparation of lipoplexes applied to cells,
various amounts of liposomes and DNA were serially diluted
separately in both serum and antibiotic-free RPMI1640 or
DMEM culture medium, then the DNA solutions were added
into liposome solutions and mixed briefly by pipetting up and
down several times, after which the mixtures were incubated at
room temperature for about 30 min to obtain lipoplexes of desired
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was used at a concentration of 2 mg/well unless otherwise noted.
After 30 min of complexation, old cell culture medium was
removed from the wells, cells were washed once with serum-free
RPMI1640 or DMEM, and the above 200 mL lipoplexes were
added to each well. The plates were then incubated for 4 h at
37uC in a humidified atmosphere containing 5% CO2. At the end
of incubation period, medium was removed and 500 mL of fresh
RPMI1640 or DMEM medium containing 10% FBS was added
to each well. Plates were further incubated for a period of 24 h
before checking the reporter gene expression.
For fluorescent microscopy assays, cells were transfected by
complexes containing pEGFP-N1. After 24 h incubation, the
microscopy images were obtained at the magnification of 406and
recorded using Viewfinder Lite (1.0) software.
For luciferase assays, cells were transfected by complexes
containing pGL-3. For a typical assay in a 24-well plate, 24 h
post-transfection as described above, the old medium was removed
from the wells and the cells were washed twice with 500 mL of pre-
chilled PBS. According to Luciferase assay kit (promega)
manufacture, 100 mLo f1 6 cell lysis buffer diluted with PBS
was then added to each well, and the cells were lysed for 30 min in
a horizontal rocker at room temperature. The cell lysate was
transferred completely to Eppendorf tubes and centrifuged
(4000 rpm, RT) for 2 min; the supernatant was transferred to
Eppendorf tubes and stored in ice. For the assay, 20 mL of this
supernatant and 100 mL of luciferase assay substrate (Promega)
were used. The lysate and the substrate were both thawed to RT
before performing the assay. 20 mL lysate was added to 100 mL
substrate and the luciferase activity was measured in a luminom-
eter (Thermo Scientific Fluoroskan Ascent FL, Thermo, U.S.A.) in
standard kinetic-luminescence mode. The integration time of
measurement was 10000 ms. A delay of 2 s was given before each
measurement. Each well was measured for 8 times. The protein
concentration in the cell lysate supernatant was estimated in each
case with Thermo Modified Lowry Protein Assay Kit (Thermo,
Rockford, IL, USA). Comparison of the transfection efficiencies of
the individual lipids was made based on data for luciferase
expressed as relative light units (RLU)/mg of protein. All the
experiments were done in triplicates, and results presented are the
average of at least two such independent experiments done on the
same days.
Cytotoxicity assays
Toxicity of lipoplexes toward A549, Hep G2, H460 and
HEK293 cells was determined using MTT (3-(4, 5-dimethylthia-
zol-2-yl)-2, 5-diphenyltetrazolium bromide) reduction assay fol-
lowing literature procedures [26,27]. About 4500–6000 cells/well
were seeded into 96-well plates. After 24 h, optimized lipid/
DOPE formulations were complexed with 0.5 mg of DNA at
various N/P ratios for 30 min. 100 mL of lipoplexes were added to
the cells in the absence of serum. After 4 h of incubation, lipoplex
solutions were removed and 200 mL of media with 10% FBS was
added. After 24 h, 20 mL of MTT solution was added and the cells
were incubated further for 4 h. Blue formazan crystals were seen
at well when checked under microscope. Media were removed and
150 mL of DMSO was added per well and then plates was
incubated on a shaker for 10 min at room temperature to dissolve
blue crystal. The absorbance was measured using a microtiter
plate reader. The % viability was then calculated as [A490(treated
cells)-background]/[A490(Untreated cells)-background]6100. The
cytotoxicity of lipoplexes prepared from Lipofectamine 2000
TM
was used as control, which was prepared based on the standard
conditions specified by the manufacturer.
Results and Discussion
Chemistry
Three novel cyclen-based cationic lipids (L1–L3) were designed
and synthesized by using protonated cyclen and imidazolium salt
group as the headgroup of cationic lipids (As shown in Figure 1).
All cationic lipids have the same hydrophilic headgroup
(protonated cyclen and imidazolium salt). Their hydrophobic
alkyl chains were connected to the headgroup via methylene (L1)
or ester groups (L2 and L3), and the sole structural difference
between L2 and L3 is the orientation of the ester group. Cyclen
derivatives, which was extensively studied in our group for their
synthesis and interaction with DNA [21,28–31] was introduced
here because protonated cyclen has pH-dependent charged
nitrogen, centralized amine density and non-folded conformations
which would make against their interactions with DNA [18]. All
cationic lipids were synthesized according to Scheme S1.
Halogenated derivatives (1b and 1c) were firstly prepared through
ester reaction between corresponding alcohols (1-dodecanol or 2-
chloroethyl alcohol) and acyl chloride (chloroacetyl chloride or
lauroyl chloride). Lauroyl chloride was prepared as described in
literature [25]. With potassium iodide as catalyst, halogen
derivatives 1 reacted with imidazole in the presence of sodium
carbonate under 90uC in chloroform and dimethyl sulfoxide
(DMSO) for about 10 h to give imidazole derivatives 2.
Subsequently reaction between 2 and compound 3 in acetonitrile
led to the Boc-protected cyclen-imidazolium compounds 4. The
final products L1–L3 were obtained by removing the Boc groups
in methylene dichloride containing trifluoroacetic acid. All lipid
Figure 2. Electrophoretic gel retardation assays of liposomes/
DNA complexes (lipoplexes). The N/P ratios are indicated at the top
of each lane. All lipid/DOPE ratios were 1 : 2 and the concentration of
DNA was 5 mg/well.
doi:10.1371/journal.pone.0023134.g002
Figure 3. Release of the ethidium bromide (EB) from the CT
(calf thymus) DNA-EB complexes upon addition of the
liposomes (L1–L3) at different N/P ratios. All lipid/DOPE ratios
were 1 : 2 and the concentration of CT-DNA was 11 mM.
doi:10.1371/journal.pone.0023134.g003
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1H-NMR,
1C-NMR, ESI-MS
and IR.
Physicochemical characterizations of liposome/DNA
complexes (lipoplexes)
The formation of lipoplexes between cationic liposomes and
DNA was firstly confirmed by gel retardation assay. The
electrophoretic gel patterns revealed an interesting feature. As
shown in Figure 2, L1 and L3-based liposome were capable of
completely inhibiting electrophoretic mobility of DNA at the N/P
ratios of 4. In contrast, L2 was found to be unable to inhibit the
electrophoretic mobility of DNA even at high N/P ratios of 8,
indicating a relatively weaker affinity of L2 to DNA.
Ethidium bromide (EB) intercalation assay was also conducted
to further investigate the interaction between liposomes and
DNA. As shown in Figure 3, L2-based liposome showed a
relatively weak and linear decrease of EB fluorescence intensity as
a function of N/P ratios, which was according with the gel
electrophoresis results that indicated its relatively weaker
interaction with DNA. However, L1 and L3-based liposome
showed a sharp decrease of EB fluorescence at N/P ratio of 1 and
2, respectively. Thus, in accordance with the gel electrophoresis
data, it was confirmed that L1 and L3 could bind strongly to
DNA by showing a significant level of DNA condensation. The
order of binding abilities of those liposomes to DNA is
L1.L3.L2. By taking into account that three cationic lipids
have the same hydrophilic head groups hydrophobic alkyl chains,
the order of binding abilities is probably connected with the order
of hydrophobicity of linker group (L1.L3.L2), which in turn
favors their self-assembly and their cooperative interaction with
DNA [32].
According to DLS data shown in Figure 4, L1 and L3-based
liposomes could self-assemble into nanoparticles (around 100–
300 nm) with DNA at various N/P ratios (as in gel retardation
assay). In comparison, the particles of L2/DNA had bigger size
around 400–550 nm especially at relatively higher N/P ratio of 6
and 8 (Figure 4A), which is probably due to the weak interaction
between L2 and DNA. The negative zeta potentials of L2/DNA
at various N/P ratios (from 1–8) also demonstrated their invalid
self-assembly (Figure 4B). In contrast, the zeta potentials of L1 and
L3/DNA lipoplexes reversed to positive (from +5m Vt o+20 mV)
at N/P ratios from 4 to 8 (Figure 4B). The zeta potential results
were conformed to the above gel retardation assay and EB
intercalation assay.
To get further insights into the formed lipoplexes, we also
performed electron microscopy of lipoplexes at lipid/DOPE/ratio
of 1 : 2 with N/P ratio of 6. Representive electron micrographs of
lipoplexes were shown in Figure 5. The lipoplexes formed from L1
and L3 showed homogeneous spherical particles with the sizes in
the range of 200 to 400 nm. Meanwhile, the lipoplex prepared
from L2 formed bigger particles (around 800 nm) and showed a
tendency to aggregate. These results also suggested that comparing
to L1 and L3, lipid L2 is not a good candidate for DNA
condensation. It was also demonstrated that the little difference in
structure (ester orientation) might have large influence on the
liposome formation and subsequent DNA affinity.
Figure 4. Particle sizes (A) and zeta-potentials (B) of lipid/DOPE/DNA complexes at different N/P ratios by DLS. All lipid/DOPE ratios
were 1 : 2 and the concentration of DNA was 5 mg/well.
doi:10.1371/journal.pone.0023134.g004
Figure 5. Representive transmission electron micrographs of the lipoplexes prepared from L1 (A), L2 (B) and L3 (C). Lipid/DOPE ratios
were 1 : 2 and concentration of DNA was 2 mg, the N/P ratio was 6 for all lipoplexes.
doi:10.1371/journal.pone.0023134.g005
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The in vitro transfection abilities of title lipids were initially
studied by using green fluorescent protein reporter gene pEGFP-
N1 as guest gene and A549 as target cells. In the experiments of
L1–L3 mediated GFP expression, N/P ratios were varied from 0.5
to 20 for all lipoplexes. Figure 6 shows the images taken under the
N/P ratio range in which best results for each lipoplex were
obtained. Results indicated that L1 and L3-based lipoplexes could
lead to obvious GFP expression at N/P ratio of 1.5–2.5 and 8–12
respectively, while L2-based lipoplexes was found to be nearly
incompetent for transfection at all studied N/P ratios. For L1 and
L3, under the N/P ratios not shown in Figure 6, fewer cells that
expressed GFP were observed by microscopy.
Besides chemical structure of cationic lipids and the N/P ratios,
the mole ratio of cationic/neutral lipids in the liposome also has
large influence on the transfection efficiency [33]. We carried out a
luciferase transfection experiments by varying the mole ratios of
the cationic lipids against DOPE at the N/P ratio of 2 (L1 and L2)
Figure 6. Representative fluorescent microscope images (406) of A549 cells transfected by L1 at N/P ratio of 1.5 (A), 2 (B), 2.5 (C), L2
at N/P ratio of 2 (D), 2.5 (E), 3 (F) and L3 at N/P ratio of 8 (G), 10 (H), 12 (I). The lipid/DOPE ratios were 1 : 1 and the concentration of DNA was
2 mg/well.
doi:10.1371/journal.pone.0023134.g006
Figure 7. Transfection efficiencies of lipoplexes formed from L1–L3 at various lipid/DOPE ratios by keeping the N/P ratio at 2 (for L1
and L2) and 10 (for L3) in A549 cells. Concentration of the DNA was 2 mg/well. Data are expressed as relative light units (RLU)/mg of protein.
doi:10.1371/journal.pone.0023134.g007
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Figure 7, lipoplexes formed from L1 and L3 were found to show
maximum transfection efficiency at lipid/DOPE mole ratio of 1 :
2, whereas L2-based lipoplexes still showed nearly no transfection
across all lipid/DOPE ratios. The higher transfection efficiency
could be due to cells expressing a higher level of the delivered gene
or a greater proportion of cells being transfected, or a combination
of both [34]. Since the numbers of cells transfected by L1 and L3
were found to be comparable (As shown in Figure 6), while L3
showed appropriately 10 times higher transfection efficiency than
that of L1 under lipid/DOPE mole ratio of 1 : 2, we speculated
that L3 might induce a higher level of the delivered gene into cells.
In addition, L1-based lipoplexes was found to have no gene
transfection activities at other lipid/DOPE ratio except 1 : 2, and
all lipoplexes exhibited no transfection in the absence of DOPE.
After the confirmation of the optimum amount of DOPE (1 : 2,
L1–L3/DOPE), the effect of N/P ratios for these cationic lipids
was further investigated by luciferase transfection experiments.
Similar to the results of pEGFP-N1 assays, Figure 8 showed that
L1 and L3-based lipoplexes gave the best transfection efficiency at
N/P ratio of 2 and 10, respectively. Meanwhile, L2-based
lipoplexes only showed very low transfection activitiy at the N/P
ratio of 2. Under the optimized conditions including DOPE
amount and N/P ratio, the transfection efficiency of L3 was 3.8
Figure 8. Transfection efficiencies of L1–L3 at various N/P ratios using optimized lipid/DOPE ratio of 1 : 2 in A549 cells. Concentration
of the DNA was 2 mg/well and lipofectamine 2000
TM was used as control. Data are expressed as relative light units (RLU)/mg of protein.
doi:10.1371/journal.pone.0023134.g008
Figure 9. Transfection efficiencies of L1 and L3 at various amount of DNA using optimized lipid/DOPE ratio of 1 :2 (for L1 and L3)
and optimized N/P ratio of 2 (for L1) and 10 (for L3) in A549 cells. Data are expressed as relative light units (RLU)/mg of protein.
doi:10.1371/journal.pone.0023134.g009
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the popular commercially available gene delivery agent Lipofecta-
mine 2000
TM. Obviously, lipid L3 was found to be the best
effective gene delivery agent in this series of protonated cyclen and
imidazolium salt-based single tail cationic lipids. For comparison
between L1 and L3, the main difference in their structures is that
L3 has an ester bond which not exists in the structure of L1. The
two compounds also have similar DNA-binding ability, similar
particle sizes and zeta potentials of their formed lipoplexes. The
different gene transfection performance of L1 and L3 might be
attributed to the change in the balance between hydrophilicity and
hydrophobicity of the cationic lipids, which was originated from
their different linker group and their different aggregation
performance [32]. More interestingly, the sole structural difference
between L2 and L3, which led to their completely different gene
transfection efficiencies, is the orientation of ester group. This
result is consistent with that obtained by Rajesh et al [35] who
demonstrated for the first time that even a minor structural
variation such as linker orientation reversal in cationic lipids can
profoundly influence DNA-binding characteristics, membrane
rigidity, membrane fusibility, cellular uptake, and consequent
gene delivery efficacies of the cationic liposomes and lipoplexes.
It was reported that the amount of DNA used in transfection
experiments may also affects the transfection efficiency of cationic
lipids [32]. In all transfection experiment above, 2 mg/well of
DNA was used. To see the effect of DNA amount on the
transfection efficiency of these cationic lipids, we also performed
luciferase transfection experiments using L1 and L3 at the
optimized conditions. As shown in Figure 9, the DNA amounts
were varied from 0.5 to 2.5 mg/well. Decreased transfection
efficiencies were observed in the experiments using the amounts of
DNA of 0.5, 1, 1.5 and 2.5 mg/well. When 0.5 mg/well of DNA
was used, nearly no transfection activities for both of the lipids
were found. These results indicated that 2 mg/well of DNA was
the optimal DNA concentrations in the transfection employing L1
and L3.
To further explore the transfection efficacy of L1 and L3,
luciferase reporter gene delivery studies were carried out in three
other cell lines including Hep G2 (human hepatocellular
carcinoma), H460 (human lung cancer cells) and HEK293
(human embryonic kidney cells). As shown in Figure 10A and
10B, L3-based lipoplexes showed comparable transfection effi-
ciencies as to Lipofectamine 2000
TM in cancer cells Hep G2 and
H460, whereas L1-based lipoplexes only gave dramatically
decreased transfection efficiencies, especially in Hep G2 cells. To
our surprise, L1 and L3 were both found to be nearly futile in the
transfection towards normal cells HEK293 (Figure 10C). These
results gave us positive information that L3 displayed tumor cell-
targeting property, which still need further experiments to be
confirmed. Anyway, L3 was further proved to be a promising gene
delivery reagent.
Cytotoxicity
MTT-based cytotoxicity studies were performed in all four
studied cell lines using optimized DOPE amount at different N/P
ratios. The cytotoxicity of lipoplexes formed from Lipofectamine
2000
TM, which was prepared based on the standard conditions
specified by the manufacture, was used as control. As shown in
Figure 11, for the four cell lines studied here, in most cases, the cell
viability varied from 70% to 98%, which were similar to or slightly
higher than that caused by Lipofectamine. The exception was
found in Hep G2 cells, in which the cell viabilities of three lipid-
based lipoplexes were slightly lower than Lipofectamine, especially
at high N/P ratios. Among the three lipids, despite its poor
transfection efficiency, the polyplex formed from L2 displayed
relatively lower cytotoxicity.
Conclusion
In summary, three novel cationic lipids (L1–L3)w i t h
protonated macrocyclic polyamine (cyclen) and imidazolium salt
Figure 10. Transfection efficiencies of L1 and L3-based
lipoplexes using optimized lipid/DOPE ratio of 1 :2 (for L1
and L3) and optimized N/P ratio of 2 (for L1) and 10 (for L3) in
Hep G2 (A), H460 (B) and HEK293 (C) cells. Concentration of the
DNA was 2 mg/well and lipofectamine 2000
TM was used as control
(Lipo). The data are expressed as relative light units (RLU)/mg of protein.
doi:10.1371/journal.pone.0023134.g010
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were designed and easily prepared. In association with DOPE,
L1 and L3 could well bind and condense DNA in to
nanoparticles with the sizes of around 200 nm and zeta-
potentials of 5–20 mV. TEM also showed well-shaped spherical
particles formed from L1, L3 and DNA. In contrast, L2 could
not bind to DNA well, which was confirmed by gel retardation
assays, fluorescent quenching experiments, DLS and TEM. Of
the three lipids, the lipoplex formed from L3 was found with
high efficiency in gene transfer in three tumor cell lines including
A549, Hep G2 and H460. The optimized gene transfection
efficacy of L3 was nearly 5.5 times more efficient than that of the
popular commercially available gene delivery agent Lipofecta-
mine 2000
TM in A549 cells. Meanwhile, L1 and L3 had nearly
no gene transfection performance in normal cells HEK293,
indicating that these lipids displayed tumor cell-targeting
property, which still need further experiments to be confirmed.
No significant cytotoxicity was found for the lipoplexes formed
by L1–L3 in four cell lines, and their cytotoxicities were
similar to or slightly lower than the lipoplexes prepared
from Lipofectamine 2000
TM. These studies may extend the
application areas of macrocyclic polyamines, especially for
cyclen. Further investigations including the deep-insight studies
towards the cell-targeting delivery and more structure-activity
relationship of this type of cationic lipids are now in progress.
Supporting Information
Scheme S1 Synthetic procedures of title compounds L1–
L3.
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